Zelira Therapeutics (AU:ZLD) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Zelira Therapeutics reported a net cash inflow of $586,000 for the quarter ending September 2024, driven primarily by $2,098,000 in proceeds from borrowings. However, the company faced significant cash outflows from operating activities amounting to $1,555,000, indicating a challenging financial quarter despite the influx from financing activities.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.
